Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mix Japan Survey: 90% Of 2014 Drugs That Fall Under New Drug Premium Were Also Applicable In 2010-2013

This article was originally published in PharmAsia News

Executive Summary

Based on a questionnaire to Japanese pharmaceutical companies carried out by Mix, 90% of the drugs that applied for the premium to promote the development of new drugs and eliminate off-label use in the 2014 drug price reforms were also applicable in the three consecutive years since 2010.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts